PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carlos Quezada-Ruiz, MD, FASRS, of Genentech/Roche shares an update on Susvimo and the port delivery platform.
Quezada-Ruiz reviewed positive study outcomes seen with Susvimo (ranibizumab injection 100 mg/mL, Genentech) for the treatment of neovascular age-related macular degeneration, diabetic retinopathy and diabetic macular edema.
“Susvimo is the only sustained delivery and continuous drug delivery system that has shown positive data across three different phase 3 pivotal trials in DR, DME and